[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-motor-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-motor-dysfunction":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100474242",false,"NCT05455359","Gastrointestinal Dysmotility on Aspiration Risk","The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms","Inclusion Criteria:\n\n1. are 5-21 years of age;\n2. receive \\>90% of their calories by enteral tube (i.e., patients take no food or drink by mouth);\n3. are determined to be at high risk for aspiration pneumonia based on evidence of impaired airway protective mechanisms, documented by aspiration on video fluoroscopic swallow study;\n4. have static neurologic impairment, defined as functional and\u002For intellectual impairment that results from a chronic neurologic or related diagnosis (e.g., cerebral palsy) with no prospect of progression for at least one year;\n5. have chronic respiratory symptoms, defined as coughing, choking, or need for oral suctioning a minimum of three times per week during the prior four weeks.\n\n   \\-\n\nExclusion Criteria:\n\n1. have progressive neurologic impairment;\n2. have a history of prior intact Nissen fundoplication;\n3. are currently taking oral or inhaled antibiotics, including prophylactic antibiotics;\n4. are currently taking or have taken in the last four weeks acid suppression (H2 antagonist or PPI); or\n5. are fed by gastrojejunostomy rather than by gastrostomy. -","ALL","5 Years","21 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.",[26,27,28,29],"Esophageal Motility Disorders","Gastric Motor Dysfunction","Aspiration Pneumonia","Gastro Esophageal Reflux","RECRUITING","2025-12-23",{"date":33,"type":34},"2025-12-26","ACTUAL",{"date":36,"type":34},"2025-02-13",{"date":38,"type":20},"2027-05-31",{"name":40,"class":41},"Boston Children's Hospital","OTHER",""]